Potential Drug Induced Liver Injury (Dili) Event During Remdesivir Treatment in Covid-19 Patients

Ulvi Nur Rista, Desi Setyowati, Julaeha

2022

Abstract

The global pandemic of COVID-19 has already caused about 1.4 million deaths, and liver injury was one of the foremost problems due to antiviral treatment besides mortality. Remdesivir was one of the antivirals approved for COVID-19 treatment. Nevertheless, some studies reported that remdesivir caused liver injury. This study aimed to identify the pattern and severity of liver toxicity during remdesivir treatment. The study adopted a retrospective cohort design conducted in Mitra Keluarga Kenjeran Hospital Indonesia. This study involved patients with COVID-19 on remdesivir treatment between June and August 2021. Patients with liver impairment or abnormal alanine aminotransferase (ALT) were excluded. We described the severity of liver toxicity based on the grading system and analyzed the comparison of baseline ALT and end-point ALT using the t-test/Wilcoxon test. The 83 patients were included in this study. Our study showed ALT elevation was observed in 21 patients (25.3%), including grade 1 in 14 patients (66.7%), grade 2 in 6 patients (28.6%), and grade 3 in 1 patient (4.7%). Median end-point ALT value was significantly higher than median baseline ALT (p-value < 0.001). The finding of this study suggests that monitoring of liver function tests must be considered before the start of remdesivir treatment.

Paper Citation

in Harvard Style

Rista U., Setyowati D. and Julaeha. (2022). Potential Drug Induced Liver Injury (Dili) Event During Remdesivir Treatment in Covid-19 Patients. In Proceedings of the 3rd International Seminar and Call for Paper (ISCP) UTA ’45 Jakarta - Volume 1: ISCP UTA'45 Jakarta; ISBN 978-989-758-654-5, SciTePress, pages 372-375. DOI: 10.5220/0012025400003582

in Bibtex Style

@conference{iscp uta'45 jakarta22,
author={Ulvi Nur Rista and Desi Setyowati and Julaeha},
title={Potential Drug Induced Liver Injury (Dili) Event During Remdesivir Treatment in Covid-19 Patients},
booktitle={Proceedings of the 3rd International Seminar and Call for Paper (ISCP) UTA ’45 Jakarta - Volume 1: ISCP UTA'45 Jakarta},
year={2022},
pages={372-375},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0012025400003582},
isbn={978-989-758-654-5},
}

in EndNote Style

TY - CONF

JO - Proceedings of the 3rd International Seminar and Call for Paper (ISCP) UTA ’45 Jakarta - Volume 1: ISCP UTA'45 Jakarta
TI - Potential Drug Induced Liver Injury (Dili) Event During Remdesivir Treatment in Covid-19 Patients
SN - 978-989-758-654-5
AU - Rista U.
AU - Setyowati D.
AU - Julaeha.
PY - 2022
SP - 372
EP - 375
DO - 10.5220/0012025400003582
PB - SciTePress